← Search & browse all drugs

technetium (99mTc) hynic-octreotide

V09IA07

Forms & Strengths

Kit for radiopharmaceutical preparation
Lyophilized powder containing hydrazinonicotinyl-yl-3-benzyl-cys-dphe-cys-tyr-dtrp-lys-thr-cys-thr-ol (HYNIC-TOC)
Requires reconstitution with sodium pertechnetate (99mTc) injection

Adult Dosing

Diagnostic imaging: 370 to 740 MBq (10 to 20 mCi) administered via intravenous injection
Imaging typically performed 2 to 4 hours post-injection

Pediatric Dosing

Safety and efficacy in pediatric patients have not been established
Dosing in children must be adjusted based on body weight or surface area according to national nuclear medicine guidelines if used off-label

Indications

Localization of somatostatin receptor-expressing neuroendocrine tumors (NETs)
Staging and re-staging of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Detection of primary tumors and metastases expressing somatostatin receptors

Mechanism of Action

Radiolabeled somatostatin analogue that binds with high affinity to somatostatin receptors (primarily subtype sstr2)
Gamma emission from technetium-99m allows for visualization of receptor-positive tissues via single-photon emission computed tomography (SPECT)

Contraindications

Hypersensitivity to the active substance, any excipients, or technetium-99m
Known pregnancy

Adverse Reactions

Generally well tolerated with very low incidence of adverse effects
Transient flushing, dizziness, or nausea occasionally reported
Rare hypersensitivity or anaphylactoid reactions

Drug Interactions

Unconjugated somatostatin analogues (e.g., octreotide) can competitively block binding to somatostatin receptors, potentially reducing diagnostic efficacy
Discontinuation of short-acting somatostatin analogues 24 to 48 hours prior to imaging is often recommended
Long-acting analogues should ideally be timed just before the next scheduled dose

Curated Content: Needs Vetting Before Put to Clinical Use